NasdaqGS:COLLPharmaceuticals
A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed
Collegium Pharmaceutical (COLL) is back in focus after reporting first quarter 2026 earnings that showed a sharp jump in profitability and progress across its ADHD and pain portfolios, alongside a proposed AZSTARYS acquisition.
See our latest analysis for Collegium Pharmaceutical.
Despite the strong first quarter earnings and the proposed AZSTARYS deal, Collegium Pharmaceutical’s share price performance has been mixed. The 7 day share price return was 9.31%, but the 90 day share price return...